(HealthDay)—For patients with noninvasive urothelial carcinoma, three DNA methylation markers are able to accurately predict tumor recurrence, according to a study published in the April 1 issue of Clinical Cancer Research.
Sheng-Fang Su, from USC Norris Comprehensive Cancer Center at the University of Southern California in Los Angeles, and colleagues analyzed DNA methylation levels of six markers in 368 urine sediment samples from 90 patients with noninvasive urothelial carcinoma to assess their use in longitudinal tumor recurrence surveillance. Five-fold cross-validation was used to identify the optimum marker combination, which was then validated in separate samples.
The researchers identified a panel of three markers which were able to discriminate between patients with and without recurrence. The area under the curve was 0.90 in the testing set and 0.95 in the validation set, while sensitivity was 86 and 89 percent and specificity 80 and 97 percent, respectively. Tumor recurrence was reliably predicted by the three-marker test in 80 percent of patients, which was superior to cytology and cystoscopy (35 and 15 percent, respectively). The test accurately predicted no recurrence for 74 percent of patients who scored negative on the test.
"Given their superior sensitivity and specificity in urine sediments, a combination of hyper- and hypomethylated markers may help avoid unnecessary invasive exams and reveal the importance of DNA methylation in bladder tumorigenesis," the authors write.
One author disclosed financial ties to the pharmaceutical industry.
Explore further: Certain genetic variants may put bladder cancer patients at increased risk of recurrence
More information: Abstract
Full Text (subscription or payment may be required)
Copyright © 2014 HealthDay. All rights reserved.
Medical Xpress on facebook
Related Stories
Certain genetic variants may put bladder cancer patients at increased risk of recurrence
Mar 26, 2014
In the Western world, bladder cancer is the fourth most common cancer in men and the eighth most common in women, with many patients experiencing recurrence after treatment. A new study published in BJU International indica ...
RNA assays up sensitivity of urothelial carcinoma detection
Aug 21, 2012
(HealthDay) -- Cxbladder, a derivative of the RNA assay uRNA, may be an effective alternative to cytology and nuclear matrix protein 22 (NMP22) assays for the detection of urothelial carcinoma, according to a s ...
More accurate markers identified for detecting response to epigenetic drugs for myelodysplastic syndromes
Apr 08, 2013
Researchers have identified and validated two DNA methylation markers that could help physicians to more accurately determine a patient's response to epigenetic drugs for treatment of myelodysplastic syndromes (MDS), according ...
Biomarkers predict time to ovarian cancer recurrence
Aug 15, 2013
Ovarian cancer often remains undetected until it is at an advanced stage. Despite positive responses to initial treatment, many patients are at risk of tumor recurrence. A multitude of genetic markers have been implicated ...
Low rates of recurrence with 'no ink' as margin in breast CA
Feb 14, 2014
(HealthDay)—Positive margins (ink on invasive carcinoma or ductal carcinoma in situ) are associated with increased risk of ipsilateral breast tumor recurrence (IBTR), according to consensus guidelines published ...
Recommended for you
World-first clinical trial launches for advanced bowel cancer
36 minutes ago
Patients with advanced bowel cancer are set to benefit from the launch of a revolutionary new clinical trial targeting treatments to their specific cancer type as well as rapidly adapting to include new drugs ...
Cell metabolism discovery could lead to treatments for cancer, common cold
1 hour ago
(Medical Xpress)—Scientists at UCLA's Jonsson Comprehensive Cancer Center have published the first study explaining in detail how viruses reprogram the metabolism of the cells they invade to promote continued viral growth ...
The Sun's campaign may actually harm women
13 hours ago
A breast check campaign by The Sun newspaper may actually harm women, warns Glasgow general practitioner Margaret McCartney today.
Screening for liver cancer in patients with cirrhosis
14 hours ago
In a systematic review and meta-analysis of 47 studies with 15,158 patients, Amit Singal (University of Texas Southwestern Medical Center) and colleagues found that patients with cirrhosis who underwent surveillance (via ...
Likely culprit in spread of colon cancer identified
14 hours ago
New research at Washington University School of Medicine in St. Louis and Vanderbilt University Medical Center in Nashville has implicated a poorly understood protein called PLAC8 in the spread of colon cancer.
Experts question routine mammograms in elderly
15 hours ago
Doctors should focus on life expectancy when deciding whether to order mammograms for their oldest female patients, since the harms of screening likely outweigh the benefits unless women are expected to live at least another ...
User comments
© Medical Xpress 2011-2014, Science X network
(HealthDay)—For patients with noninvasive urothelial carcinoma, three DNA methylation markers are able to accurately predict tumor recurrence, according to a study published in the April 1 issue of Clinical Cancer Research.
Sheng-Fang Su, from USC Norris Comprehensive Cancer Center at the University of Southern California in Los Angeles, and colleagues analyzed DNA methylation levels of six markers in 368 urine sediment samples from 90 patients with noninvasive urothelial carcinoma to assess their use in longitudinal tumor recurrence surveillance. Five-fold cross-validation was used to identify the optimum marker combination, which was then validated in separate samples.
The researchers identified a panel of three markers which were able to discriminate between patients with and without recurrence. The area under the curve was 0.90 in the testing set and 0.95 in the validation set, while sensitivity was 86 and 89 percent and specificity 80 and 97 percent, respectively. Tumor recurrence was reliably predicted by the three-marker test in 80 percent of patients, which was superior to cytology and cystoscopy (35 and 15 percent, respectively). The test accurately predicted no recurrence for 74 percent of patients who scored negative on the test.
"Given their superior sensitivity and specificity in urine sediments, a combination of hyper- and hypomethylated markers may help avoid unnecessary invasive exams and reveal the importance of DNA methylation in bladder tumorigenesis," the authors write.
One author disclosed financial ties to the pharmaceutical industry.
Explore further: Certain genetic variants may put bladder cancer patients at increased risk of recurrence
More information: Abstract
Full Text (subscription or payment may be required)
Copyright © 2014 HealthDay. All rights reserved.
Medical Xpress on facebook
Related Stories
Certain genetic variants may put bladder cancer patients at increased risk of recurrence
Mar 26, 2014
In the Western world, bladder cancer is the fourth most common cancer in men and the eighth most common in women, with many patients experiencing recurrence after treatment. A new study published in BJU International indica ...
RNA assays up sensitivity of urothelial carcinoma detection
Aug 21, 2012
(HealthDay) -- Cxbladder, a derivative of the RNA assay uRNA, may be an effective alternative to cytology and nuclear matrix protein 22 (NMP22) assays for the detection of urothelial carcinoma, according to a s ...
More accurate markers identified for detecting response to epigenetic drugs for myelodysplastic syndromes
Apr 08, 2013
Researchers have identified and validated two DNA methylation markers that could help physicians to more accurately determine a patient's response to epigenetic drugs for treatment of myelodysplastic syndromes (MDS), according ...
Biomarkers predict time to ovarian cancer recurrence
Aug 15, 2013
Ovarian cancer often remains undetected until it is at an advanced stage. Despite positive responses to initial treatment, many patients are at risk of tumor recurrence. A multitude of genetic markers have been implicated ...
Low rates of recurrence with 'no ink' as margin in breast CA
Feb 14, 2014
(HealthDay)—Positive margins (ink on invasive carcinoma or ductal carcinoma in situ) are associated with increased risk of ipsilateral breast tumor recurrence (IBTR), according to consensus guidelines published ...
Recommended for you
World-first clinical trial launches for advanced bowel cancer
36 minutes ago
Patients with advanced bowel cancer are set to benefit from the launch of a revolutionary new clinical trial targeting treatments to their specific cancer type as well as rapidly adapting to include new drugs ...
Cell metabolism discovery could lead to treatments for cancer, common cold
1 hour ago
(Medical Xpress)—Scientists at UCLA's Jonsson Comprehensive Cancer Center have published the first study explaining in detail how viruses reprogram the metabolism of the cells they invade to promote continued viral growth ...
The Sun's campaign may actually harm women
13 hours ago
A breast check campaign by The Sun newspaper may actually harm women, warns Glasgow general practitioner Margaret McCartney today.
Screening for liver cancer in patients with cirrhosis
14 hours ago
In a systematic review and meta-analysis of 47 studies with 15,158 patients, Amit Singal (University of Texas Southwestern Medical Center) and colleagues found that patients with cirrhosis who underwent surveillance (via ...
Likely culprit in spread of colon cancer identified
14 hours ago
New research at Washington University School of Medicine in St. Louis and Vanderbilt University Medical Center in Nashville has implicated a poorly understood protein called PLAC8 in the spread of colon cancer.
Experts question routine mammograms in elderly
15 hours ago
Doctors should focus on life expectancy when deciding whether to order mammograms for their oldest female patients, since the harms of screening likely outweigh the benefits unless women are expected to live at least another ...
User comments
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment